The discovery by Janeway and Medzhitov that innate immune cells sense pathogens through pattern recognition receptors (PRRs) has revolutionized our understanding of the role of the innate immune system in infection and in driving T cell responses 1 . It has also significantly enhanced our understanding of the mechanisms of immune dysregulation that promote autoimmunity. Organ-specific autoimmune diseases can develop through a combination of hereditary and environmental factors that lead to a failure to regulate adaptive immune responses to self antigens, in particular those mediated by T helper 17 (T H 17) cells, which produce interleukin-17 (IL-17) 2 . The mechanism is thought to involve a breakdown of immunological tolerancemainly owing to defective regulatory T (T Reg ) cell function -and this leads to the uncontrolled generation of autoantigen-specific antibodies and pathogenic T cells that mediate tissue inflammation 3 . Inflammatory T cells are induced by molecules derived from pathogens or commensal microorganisms, as well as by endogenous stress-induced self molecules. These respective microorganism-associated molecular patterns (MAMPs) and damage-associated molecular patterns (DAMPs) induce inflammatory T cells either indirectly, through the induction of pro-inflammatory cytokine production by innate immune cells, or directly, by binding to PRRs on T cells. Evidence for this is provided by the described associations between infection and autoimmune diseases (such as multiple sclerosis and rheumatoid arthritis), which develop following the activation of self-reactive B and T cells, and between infection and chronic inflammatory diseases (such as Crohn's disease), which result from uncontrolled innate and adaptive immune responses to normal constituents of the gut microbiota.
. The mechanism is thought to involve a breakdown of immunological tolerancemainly owing to defective regulatory T (T Reg ) cell function -and this leads to the uncontrolled generation of autoantigen-specific antibodies and pathogenic T cells that mediate tissue inflammation 3 . Inflammatory T cells are induced by molecules derived from pathogens or commensal microorganisms, as well as by endogenous stress-induced self molecules. These respective microorganism-associated molecular patterns (MAMPs) and damage-associated molecular patterns (DAMPs) induce inflammatory T cells either indirectly, through the induction of pro-inflammatory cytokine production by innate immune cells, or directly, by binding to PRRs on T cells. Evidence for this is provided by the described associations between infection and autoimmune diseases (such as multiple sclerosis and rheumatoid arthritis), which develop following the activation of self-reactive B and T cells, and between infection and chronic inflammatory diseases (such as Crohn's disease), which result from uncontrolled innate and adaptive immune responses to normal constituents of the gut microbiota.
There are several families of PRRs. Toll-like receptors (TLRs) sense conserved molecules from bacteria, viruses and parasites; the cytosolic NOD-like receptors (NLRs) sense bacterial products; C-type lectin receptors (CLRs) bind β-glucans; and RIG-I-like receptors (RLRs) bind nucleic acids 4, 5 . There have been several exciting recent discoveries that have linked the activation of PRRs with autoimmune diseases. Many of these findings have described the capacity of exogenous and endogenous ligands to promote innate inflammatory responses that drive the induction of autoreactive T cells, in particular IL-17-producing γδ T cells and T H 17 cells [6] [7] [8] [9] [10] [11] . Coupled with the discoveries regarding the pathogenic role of these IL-17-producing T cells in autoimmunity, these findings have significantly advanced our understanding of the disease process in many autoimmune disorders. TLRs are a key family of PRRs involved in driving autoimmune inflammation; therefore, inhibitors of TLR binding or signalling are now considered to have great potential as therapeutics for autoimmune and other inflammatory diseases.
This Review article discusses the role of TLRs in organ-specific autoimmune diseases in the context of the activation of autoreactive T cells either directly or via innate immune cells. In addition, it explores new immunotherapeutic approaches based on inhibiting TLR-induced immune activation.
Box 1 | Toll-like receptors -sensors of microbial molecules and danger signals
Human Toll-like receptors (TLRs) are evolutionary conserved homologues of the Drosophila melanogaster Toll protein, which is involved in embryonic development in D. melanogaster. TLRs are expressed on the cell surface or intracellularly in many cell types, especially in cells of the innate immune system, where they function as sensors of infection or damage. TLRs are members of the pattern recognition receptor (PRR) family, and they sense conserved exogenous molecules from pathogens, called pathogen-associated molecular patterns (PAMPs). In addition, TLRs bind to molecules from commensal bacteria and to endogenous damage-associated molecular patterns (DAMPs) from dead and dying cells. Ligands for TLRs include proteins, lipopeptides and nucleic acids from bacteria, viruses, fungi, parasites and human cells, as well as synthetic molecules. Examples of pathogen-derived, endogenous and synthetic TLR agonists are shown in the table.
Pathogen-associated molecular patterns (PAMPs) . Molecular patterns that are found in pathogens but not in mammalian cells. Examples include terminally mannosylated and polymannosylated compounds (which bind the mannose receptor) and various microbial components, such as bacterial lipopolysaccharide, hypomethylated DNA, flagellin and double-stranded RNA (all of which bind Toll-like receptors).
Sterile inflammation
Inflammation, characterized by leukocyte recruitment, that does not involve infection but is precipitated by the activation of innate immune cells by endogenous mediators (alarmins or DAMPs) that are released from host cells following tissue injury and necrotic cell death.
PAMPs shape innate and adaptive immunity PRRs are expressed by a variety of cell types -especially cells of the innate immune system, such as dendritic cells (DCs) and macrophages -and they function to sense danger or damage signals. The PRR ligands include conserved microbial structures, termed pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), flagellin and viral and bacterial nucleic acids. In addition, PRRs can sense DAMPs (endogenous danger signals from dead and dying cells), such as amyloid-β and saturated fatty acids
. The primary function of PRRs is to mediate innate immune responses to pathogens and tumours, but they also have a role in sterile inflammation and have been linked with autoimmune and chronic inflammatory diseases 1, 4 . Innate immune cells (especially DCs) direct the adaptive immune system, not only by acting as antigenpresenting cells (APCs) for naive T cells, but also by providing the cytokine stimulus (the third signal) for T cell activation 1, 2 . The binding of agonists to TLRs promotes both DC maturation and the production of T cell-promoting cytokines 1 via distinct signalling pathways (FIG. 1) . Activation of nuclear factor-κB (NF-κB) results in the production of pro-inflammatory cytokines, including tumour necrosis factor (TNF), IL-6, pro-IL-1β and pro-IL-18 (REFS 4, 5) . Activation of the interferon regulatory factor (IRF) pathways promotes the production of IL-12p35 and type I interferons (IFNs), whereas active extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinases are required for IL-23p19 and IL-10 production, respectively 5, 12, 13 (FIG. 1) . TLR agonists have potent immunomodulatory activity and can promote adaptive immune responses to co-administered antigens; consequently, they have been exploited as adjuvants in vaccines for infectious disease and cancer and as tumour immunotherapeutics 14, 15 . Conversely, because of the ability of TLR agonists to activate innate immune responses and inflammation, molecules that antagonize TLR ligand binding or inhibit TLR signalling pathways are being developed as therapies against autoimmune and other inflammatory diseases 5 . Targeting innate cytokines that promote pathogenic T cell responses has become a major focus in drug development for the treatment of autoimmune diseases (FIG. 2) . Whereas much of the initial focus was on IL-12, which is the key driver of pathogenic T H 1 cells, the discovery of T H 17 cells and their role in autoimmunity (BOX 2) has shifted the emphasis to the innate regulatory cytokines IL-6, IL-23 and IL-1, which promote the development of T H 17 cells. It is now recognized that IL-6 and transforming growth factor-β (TGFβ) In addition, TLR2 and TLR4 use TIR domain-containing adaptor protein (TIRAP; also known as MAL), whereas TIR domain-containing adaptor protein inducing IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM; also known as TICAM2) are required for TLR3-and TLR4-mediated type I interferon (IFN) production. The figure illustrates some of the signalling pathways induced in a dendritic cell in response to Gram-negative bacteria. Lipopolysaccharide (LPS) from the bacteria binds to TLR4 in complex with MD2, and this complex initiates signalling by recruiting the adaptor proteins MYD88, TIRAP, TRIF and TRAM. MYD88 associates with IL-1R-associated kinase 1 (IRAK1) and IRAK4 and recruits TNFR-associated factor 6 (TRAF6). This complex recruits TGFβ-activated kinase 1 (TAK1), leading to phosphorylation of NF-κB inhibitor (IκB), activation of nuclear factor-κB (NF-κB) and consequent transcription of a range of genes coding for pro-inflammatory cytokines, including tumour necrosis factor (TNF), interleukin-6 (IL-6), pro-IL-1β and pro-IL-18. In addition, TLR agonists activate the interferon regulatory factor (IRF) pathways, leading to the production of IL-12p35 and type I IFNs. TLR-induced activation of TAK1 also results in phosphorylation of mitogen-activated protein kinases (MAPKs), including p38 and extracellular signal-regulated kinase (ERK colony-stimulating factor (GM-CSF) that is produced by both T H 1 and T H 17 cells activates CD11b + myeloid cells, DCs and macrophages and appears to be essential for the development of autoimmunity. Cytokines produced by T H 1 and T H 17 cells activates macrophages, DCs and other cells, promoting the release of pro-inflammatory mediators, such as IL-1β, tumour necrosis factor (TNF), matrix metalloproteinases (MMPs) and reactive oxygen species (ROS), which mediate tissue damage. IL-17 induces the production of chemokines, especially CXC-chemokine ligand 2 (CXCL2; also known MIP2) and IL-8 (also known as CXCL8), which recruit neutrophils to the site of inflammation. Biological response-modifying drugs that are in use or in preclinical or clinical evaluation target many of the cytokines and intracellular signalling molecules in innate cells and T cells. IFNγ, interferon-γ; JAK, Janus kinase; MEK, MAPK/ERK kinase; TCR, T cell receptor; T Reg , regulatory T.
Box 2 | The role of T H 17 and T H 1 cells in autoimmunity
Before the discovery of T helper 17 (T H 17) cells, it was thought that T H 1 cells were the primary pathogenic cell population in T cell-mediated autoimmune diseases. However, mice deficient in interferon-γ (IFNγ) or interleukin-12 (IL-12) were found to have increased susceptibility to experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA) [108] [109] [110] . It was subsequently shown that Il17 -/-mice have a reduced susceptibility to EAE 111 , and that EAE can be induced in naive mice following the transfer of myelin-specific T H 17 cell populations that are isolated from mice with EAE and expanded in vitro using IL-23 (REF. 112 ). Furthermore, mice deficient in IL-23 -which is required for the expansion of T H 17 cell populations -are resistant to the induction of EAE and CIA 108, 113 . Although there is considerable plasticity in T cell subtypes, it now appears that T H 17 cells are a functionally distinct population of CD4 + T cells that are pathogenic in many autoimmune diseases 2 . There is evidence that IFNγ may suppress IL-17 production by T H 17 cells 21 . This has provided an explanation for the failure of a therapy using an IFNγ-specific blocking antibody in patients with multiple sclerosis and for the more severe EAE in Ifng -/-mice 110 . However, there is evidence from cell transfer studies that both T H 1 and T H 17 cell subsets have a pathogenic role in autoimmune inflammation, perhaps by acting at different stages of disease or by recruiting different effector cells 114 . It has also been reported that the transfer of autoreactive T H 1 cells induced experimental autoimmune uveitis (EAU) in naive recipients, and this was not inhibited by treatment with IL-17-specific blocking antibodies 115 . Furthermore, IFNγ exacerbates disease in patients with multiple sclerosis 116 , and IFNγ promotes IL-1β production by human macrophages 117 , which enhances IL-17 production by T H 
Lymphoid tissue inducer-like cells
Innate lymphoid cells that constitutively express CD4, RORγt, the IL-23 receptor, the aryl hydrocarbon receptor and CCR6, but not CD3, NK1.1, CD11b, GR1, CD11c or B220. These cells are found in the spleen and the lamina propria and are an early source of IL-17 and IL-22 in host defence and an important source of IL-22 in intestinal homeostasis.
Specific pathogen free conditions
(SPF conditions). Vivarium conditions for rodents in which an increasing number of pathogens are excluded or eradicated from the colony. These animals are maintained in the absence of most of the known chronic and latent persistent pathogens. Although this enables better control of experimental conditions related to immunity and infection, it also sets apart such animal models from pathogen-exposed humans or non-human primates, whose immune systems are in constant contact with infectious agents.
promote the differentiation of mouse T H 17 cells from naive CD4 + T cells [16] [17] [18] and that memory T H 17 cell proliferation and IL-17 production are promoted by IL-23 and either IL-1β or IL-18 (which are produced via the activation of the NLRP3 inflammasome and caspase 1 in TLR-primed DCs 8 ) 19, 20 (FIG. 3) . Moreover, it has been suggested that IL-23 can also induce the differentiation of T H 17 cells 21, 22 . As well as having an indirect role in promoting IL-17 production by T cells, there is increasing evidence that PRR-triggered innate immune cells can act as a direct source of IL-17. γδ T cells 6, 23 , natural killer T (NKT) cells 24 and lymphoid tissue inducer-like cells 25 have all been shown to be important sources of IL-17 and associated cytokines. We have demonstrated that IL-1α or IL-1β can synergize with IL-23 to promote IL-17 secretion from γδ T cells without T cell receptor (TCR) engagement 6, 19 . γδ T cells secrete IL-17, IL-21 and IL-22 and act in an amplification loop to expand T H 17 cell populations 6 . A high frequency of IL-17-producing γδ T cells are found in the central nervous system (CNS) of mice with experimental autoimmune encephalomyelitis (EAE), where they function with T H 17 cells to mediate autoimmune inflammation 6, 26 . Although much of the focus on TLRs has centred around their role in sensing infection and initiating innate immune responses, it is now clear that TLR agonists also have a crucial role in adaptive immunity. Indeed, activation of DCs and other innate immune cells through PRRs appears to be a crucial step in the induction of T cell responses to pathogens, but also in the early inflammatory responses that lead to the development of autoreactive B and T cells that mediate many autoimmune diseases.
The link between PAMPs and autoimmunity Expression of PRRs has been found in the tissues of patients with organ-specific autoimmunity. Furthermore, a polymorphism in TLR2 is associated with type 1 diabetes 27 , and polymorphisms in TLR4 and TLR9 have been described in patients with Crohn's disease 28 . Mutations in nucleotide-binding oligomerization domain 2 (NOD2) have been strongly associated with Crohn's disease, and the synergy between NOD2 and TLR9 in the activation of pro-inflammatory cytokine production by peripheral blood mononuclear cells is lost in cells from patients with the NOD2 mutation 29 . Moreover, the presence of PAMPs in tissues following infection has been associated with auto immunity. These observations provide indirect evidence that PAMPs may promote autoimmune and chronic inflammatory diseases.
Infections precipitate autoimmune diseases. There is a well-established link between infection and autoimmune diseases both in clinical settings and in animal models. This link has been attributed to either molecular mimicry between pathogen-derived antigens and self antigens or nonspecific activation of innate immunity leading to a breakdown in immunological tolerance and the development of self antigen-specific T cell and antibody responses.
Transgenic mice that express a TCR specific for a myelin-derived peptide develop spontaneous EAE when housed in conventional conditions, but not in specific pathogen free conditions (SPF conditions) 30 . This suggests that infection may precipitate autoimmunity in mice. Several studies in patients with multiple sclerosis have suggested that disease may be triggered or exacerbated by infections with pathogens such as Chlamydia pneumoniae, human herpesvirus 6 and Epstein-Barr virus (EBV). The strongest evidence comes from studies of EBV infection, as viral latent protein has been detected in the brains of patients with multiple sclerosis 31 . In patients with relapsing-remitting multiple sclerosis, there is an association between upper respiratory tract infections and relapse 32 . It has also been reported that systemic infections may trigger relapses in patients with multiple sclerosis through bystander enhancement of myelin-specific T cell responses 33 . Parvovirus B19 is considered to be one triggering factor for rheumatoid arthritis; the virus was detected by PCR in synovial biopsies from 75% of patients with rheumatoid arthritis compared with 17% of patients with osteo arthritis and other arthritides 34 . Furthermore, EBV DNA and RNA were detected in 34% of patients with rheumatoid arthritis compared with in 10% of healthy individuals 35 . Commensal microorganisms may also be involved in the development of autoimmune diseases, as suggested by the finding that some species within the gut microbiota promote the pathogenesis of inflammatory bowel disease, especially Crohn's disease 36 . Commensal microorganisms (in particular, segmented filamentous bacteria) have been shown to promote the induction of T H 17 cells 9 and, in addition to contributing to intestinal inflammation, these T H 17 cells can drive autoimmune arthritis 37 . It has also been reported that ATP derived from commensal bacteria promotes the production of IL-6, TGFβ and IL-23 by DCs, leading to local activation of 'naturally occurring' and induced T H 17 cells 38 . This response was found to be independent of TLR signalling. However, studies in a T cell transfer model of colitis showed that commensal bacteria promote T H 1 and T H 17 cell responses by activating the innate immune system via MYD88 (myeloid differentiation primary response protein 88) 39 , which is an adaptor protein for the IL-1 receptor (IL-1R) and all TLRs except TLR3. Although IL-6 was implicated in this study, a role for commensal microorganism-induced IL-1 in promoting T H 17 cell responses has not been ruled out. These studies point to a role for pathogens and commensal bacteria in promoting or exacerbating autoimmune diseases.
PAMPS may exacerbate autoimmunity. In addition to initiating autoimmune and chronic inflammatory diseases, PAMPs may exacerbate these diseases. Infection with Streptococcus pneumoniae 7 days after the induction of EAE exacerbates autoimmunity in wild-type but not Tlr2 -/-mice 40 . This suggests that pathogens may exacerbate autoimmune diseases via the activation of TLRs. Furthermore, PAMPs are present in the diseased tissues of patients with autoimmune disorders. For example, peptidoglycans, which can act as ligands for NLRs and TLR2, have been found in various cells and tissues, including in synovial tissue macrophages and DCs isolated from patients with rheumatoid arthritis 41 ; in the bowel walls of patients with Crohn's disease 42 ; in the brains of primates with EAE 43 ; and in macrophages and DCs in the brains of patients with multiple sclerosis 44 . Interestingly, the expression of some TLRs (such as TLR2 and TLR3) is enhanced in astrocytes and oligodendrocytes from patients with multiple sclerosis, suggesting that increased TLR signalling may occur during ongoing autoimmunity 45 . This in turn may further exacerbate autoimmunity. Indeed, the use of the TLR7 and TLR8 agonist imiquimod in the treatment of patients with cancer exacerbates psoriasis 46 . Some infections suppress autoimmunity. In addition to driving autoimmunity, certain infections have also been associated with the suppression of autoimmune diseases. Epidemiological data have shown that the incidence of multiple sclerosis and type 1 diabetes is increasing in developed countries, and this correlates with a decrease in the number of infections 47 . Conversely, a higher incidence of infections with helminth parasites in rural parts of developing countries is associated with a lower incidence of allergy and autoimmune diseases 48 . The so-called 'hygiene hypothesis' suggests that antiinflammatory cytokines or T Reg cells induced by such infections suppress the immune responses that mediate allergy and autoimmunity by exerting bystander effects 48, 49 . This hypothesis is supported by mouse studies showing that helminth infections can suppress autoimmunity by inducing anti-inflammatory cytokines and T Reg cells that suppress autoantigen-specific T H 17 cells 50 . It has also been shown that the infection of germ-free mice with human commensal bacteria of a single species (Bacteroides fragilis) protects against EAE through T Reg cell induction 51 . So, although much of the evidence points to a role for pathogens and commensal bacteria (especially those that induce potent T H 17 cell responses) in promoting autoimmune inflammation, chronic infections (especially with parasites that are sustained and dominated by T Reg cells) may have the opposing effect of attenuating autoimmunity.
The role of DAMPs in autoimmunity Although pathogens and their products have been implicated in precipitating autoimmune diseases in humans and can induce experimental autoimmunity in animal models, there is also evidence that DAMPs or alarmins, which are released from dead or dying cells, can stimulate innate immune responses that lead to autoimmunity (FIG. 4) . Polly Matzinger was the first to suggest that, in addition to responding to PAMPs, APCs respond to danger or alarm by recognizing endogenous molecules produced by distressed tissues, and these molecules were termed DAMPs 52 . The term alarmin was coined by Joost Oppenheim 53 to describe a group of mediators that are released by necrotic cells in response to infection or injury and that interact with PRRs to activate innate immune cells (including DCs), thereby enhancing T cell responses. It has also been suggested that alarmins are members of a larger family of danger-associated molecules that includes PAMPs 54 . High mobility group box 1 (HMGB1) is considered to be a DAMP capable of activating innate immune responses. Although there are reports that it may bind to TLR4 and other TLRs, many of the early studies on HMGB1 and other putative DAMPs were compromised by contamination with PAMPs, especially LPS. However, it has recently been reported that HMGB1 can stimulate innate immune responses by acting as a universal sentinel for nucleic acids 55 . HMGB1 binds to most or all nucleic acids and facilitates their interaction with innate immune cell PRRs, including nucleic acid-sensing TLRs (namely, TLR3, TLR7 and TLR9) and cytosolic nucleic acid-binding sensors (namely, retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), DNA-dependent activator of IRFs (DAI; also known as ZBP1) and absent in melanoma 2 (AIM2)). Interestingly, HMGB1 concentrations are elevated in the blood of patients with systemic lupus erythematosus (SLE), compared with concentrations in healthy controls, and there was a positive correlation between HMGB1 concentrations and disease activity 56 . This provides indirect evidence that this endogenous DAMP may be involved in the pathogenesis of human autoimmune diseases.
In a mouse model of neutrophilic inflammation, Chen et al. found that intraperitoneal injection of dying cells into mice induced the recruitment of neutrophils. This response was not associated with HMGB1, but was mediated through MYD88, which was activated by IL-1 rather than TLR signalling 57 . The neutrophil recruitment and the production of the hepatic enzyme alanine aminotransferase (ALT) that were observed in wild-type mice were absent in mice lacking IL-1 receptor type 1 (IL-1R1) but not in mice deficient for a range of TLRs, IL-18R or caspase 1. Moreover, the inflammatory response was blocked by an IL-1α-specific blocking antibody, suggesting that IL-1α is a key alarmin driving sterile inflammation. As IL-1α promotes IL-17 production by T cells 19 , it may be an important endogenous activator of pathogenic T cells in autoimmune diseases.
Another alarmin, 15α-hydroxycholestene (15-HC), is a derivative of cholesterol and activates microglia via TLR2 and poly(ADP-ribose) polymerase 1 (PARP1). 15-HC levels are elevated in the serum of patients during the progressive phase of multiple sclerosis and in mice with secondary progressive EAE 58 . A TLR2-specific antibody inhibited the activation of PARP1 by 15-HC and attenuated the progression of EAE 58 . Human synovial membrane cultures from patients with rheumatoid arthritis were found to express TLR2 and TLR4 and to release endogenous TLR ligands that may contribute to destructive inflammation in the joints of these patients 59 . Another alarmin with a role in this disease is heterogeneous nuclear ribonucleoprotein (hnRNP) -an RNA-and DNA-binding complex that is a target of most nuclear antigen-specific B and T cells in systemic autoimmune diseases but also in human rheumatoid arthritis and in pristane-induced arthritis in rats. Moreover, it has recently been shown that hnRNP triggers TLR7-and TLR9-mediated activation of arthritogenic APCs, which activate pathogenic T cells 60 .
Although many of the early studies on DAMPs may be compromised by contamination issues, the more recent studies using knockout mice and alarmins that have been molecularly defined suggest that DAMPs can promote innate and, as a consequence, adaptive immune responses that mediate autoimmunity. However, it is still unclear whether this sterile inflammation is sufficient to kick-start autoreactive T cell responses, or whether it amplifies responses that are induced by PAMPs.
TLRs in animal models of autoimmunity Studies using mice with defective TLR signalling, TLRspecific blocking antibodies, inhibitors of TLR signalling or TLR agonists in animal models of autoimmune diseases have provided insight into the role of TLR activation in the initiation or exacerbation of autoimmunity (TABLES 1,2).
The role of TLRs in EAE.
The active induction of EAE involves the immunization of mice with myelin-derived peptides in complete Freund's adjuvant (CFA). CFA contains killed Mycobacterium tuberculosis, and PAMPs from these bacteria activate innate immune responses, which in turn promote pathogenic autoreactive T cell responses. Studies by Prinz et al. 10 and Marta et al. 61 showed that mice deficient in the adaptor protein MYD88 are resistant to EAE. This was associated with reduced IL-6 and IL-23 production by DCs and reduced IL-17 and IFNγ production by T cells 10 (TABLE 1) . This suggests that innate immune responses that are initiated through TLR or IL-1R signalling are required for the induction of experimental autoimmunity.
Mice with a lymphoid cell-specific TLR2 deficiency are less susceptible to EAE and have reduced T H 17 responses 62 compared with wild-type controls. The reduction in disease severity and IL-17 production was even more dramatic when EAE was induced following adoptive transfer of TLR2-deficient T cells. This suggests that TLR2 signalling in T cells may be important for the induction of EAE. In addition, TLR2 may be involved in the activation of microglia, astrocytes or CNS-infiltrating macrophages during the development of EAE 58 . The study by Prinz et al. showed that disease severity is reduced in TLR9-deficient mice, although not as dramatically as in Myd88 -/-mice 10 . Moreover, disease onset was delayed in Tlr9 -/-mice following the transfer of myelin oligo dendrocyte glycoprotein (MOG)-specific T cells from wild-type mice 10 , implicating a role for TLR9-induced innate immune activation in promoting the pathogenic function of activated autoreactive T cells. Indeed, APC activation through TLR9 could break tolerance and facilitate the induction of EAE 63 . Immunization of mice with myelin proteolipid protein (PLP) in incomplete Freund's adjuvant (IFA) induces tolerance, owing to a lack of the danger signals provided in the CFA by M. tuberculosis. However, transferred lymph node cells from these tolerized mice induced EAE following stimulation with CpG-containing oligodeoxynucleotides (CpG-ODNs) 63 , providing further evidence of a proinflammatory role for TLR9 activation. This is consistent with the demonstration that TLR9 activation may circumvent tolerance and promote intestinal inflammation by suppressing the generation of T Reg cells 64 . Interestingly, the study by Marta et al. showed that mice with defective TLR9 or TLR4 signalling had increased expression of IL-6, IL-17 and IL-23, and developed severe EAE 61 , suggesting a protective role for these TLRs in this autoimmune disease. In this study, the mice were immunized once with MOG peptide, whereas in the study by Prinz et al. the mice were immunized twice, and this may have obscured the regulatory role of TLR9 (REF. 61 ). Finally, it has been reported that parenteral injection of polyinosinic-polycytidylic acid (polyI:C), a TLR3 ligand, suppressed relapsing-remitting EAE, and this was associated with IFNβ production 65 . Collectively, these findings indicate that TLR and IL-1R signalling is crucial for the induction of EAE, but that there may be redundancy between certain TLRs. Moreover, some TLRs (including TLR2 and TLR9) may have pro-inflammatory functions, whereas others (such as TLR3 and TLR9) may also have a regulatory role in EAE, depending on the stage of the disease. Compared with studies of knockout mice, studies using TLR-specific antibodies or inhibitorswhich can be used to block TLR signalling at different stages of disease -may provide a clearer picture of the potential roles of individual TLR pathways in EAE and other autoimmune diseases.
The role of TLRs in arthritis.
In most mouse models, arthritis is induced through the activation of inflammatory responses by killed bacteria or their products, and there is good evidence that this involves the activation of PRRs. In the collagen-induced arthritis (CIA) model, which is induced by immunization with collagen and CFA, M. tuberculosis in CFA provides a source of PAMPs. Staphylococcus epidermidis-derived peptidoglycans (which include TLR2 and NLR agonists) were also shown to induce acute arthritis in mice 66 . Moreover, zymosan -a polysaccharide from the cell wall of Saccharomyces cerevisiae that binds TLR2 and the CLR dectin 1 (also known as CLEC7A) -has been used to induce experimental arthritis in mice. Zymosan-induced arthritis was found to be dependent on TLR2 activation, as disease was substantially attenuated in Tlr2 -/-mice but not by treatment with laminarin, which blocks dectin 1 (REF. 67 ). In addition, injection of immunostimulatory DNA sequences into the joints of rats promoted the development of adjuvant arthritis 68 . This suggests that activation of TLR9 may also precipitate the innate immune responses that drive inflammation in the joint.
Spontaneous T cell-mediated arthritis that occurs in mice deficient for IL-1R antagonist (Il1ra -/-mice) was shown to be dependant on TLR4 activation by commensal microorganisms; germ-free mice and Tlr4 -/-Il1ra -/-double-knockout mice did not develop arthritis 11 . Furthermore, a TLR4 antagonist (LPS from Bartonella quintana) inhibited IL-1β production in the joint and attenuated arthritis in the CIA and Il1ra -/-arthritis models 69 . By contrast, Tlr2 -/-Il1ra -/-mice developed more severe disease, which was associated with increased IFNγ production by T cells and reduced T Reg cell function 11 . TLR ligands from the microbiota or generated endogenously from damaged cells may promote arthritis in Il1ra -/-mice by enhancing IL-1-driven T H 17 cell responses, whereas TLR2 activation may be protective by promoting T Reg cell function. So, unlike its role in EAE, when TLR2 signalling appears to drive inflammatory pathology, TLR2 may both promote and inhibit inflammatory T cell responses in mouse models of arthritis. However, there is more consistent evidence -from studies using a TLR4 antagonist and from studies of TLR4-deficient mice -that targeting TLR4 has potential in the treatment of arthritis.
Other autoimmune diseases.
Further studies using mouse models of autoimmunity have revealed that the contribution of TLR signalling to the initiation of autoreactive T cell responses depends on the disease type and the experimental conditions. For example,
Myd88
-/-mice are resistant to experimental autoimmune uveitis (EAU) and exhibit markedly reduced autoantigenspecific T H 1 cell responses 70 , whereas Tlr2 -/-, Tlr4
or Tlr9 -/-mice develop normal T cell responses and are susceptible to EAU. By contrast, the development of type 1 diabetes in non-obese diabetic mice is substantially reduced in the absence of TLR2 (but not in the absence of TLR4) 71 , and it appears that APCs sense β-cell apoptosis through TLR2 and thereby promote the generation of diabetogenic T cells.
Moreover, TLR2 and TLR9 were shown to have distinct pathogenic roles in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), a multisystem autoimmune disease in which neutrophil myeloperoxidase (MPO) is targeted by autoantibodies 72 . Immunization with MPO in the presence of a TLR2 agonist (the lipopeptide Pam 3 Cys) enhanced vasculitis by promoting T H 17 celldominated responses and neutrophil recruitment, whereas immunization with MPO and a TLR9 agonist (CpG-ODNs) selectively promoted T H 1 cell responses and macrophage activation 72 . Finally, topical application of the TLR7 and TLR8 agonist imiquimod in mice induces skin lesions resembling psoriasis; this was associated with epidermal expression of IL-23 and IL-17 and increased numbers of T H 17 cells in the spleen 73 . Taken together, the studies in mouse models suggest that TLR agonists may trigger autoimmunity, with the most definitive phenotype seen in Myd88 -/-mice. However, this adaptor protein is also used for IL-1 signalling, so it cannot be inferred that the protective effect of MYD88 deficiency is solely due to a loss of TLRmediated inflammation. Studies in mice that lack a single TLR gene have revealed less dramatic defects in the induction of experimental autoimmunity in a number of models, but some of the best evidence supports a role for TLR2 in EAE and type 1 diabetes, and for TLR4 in arthritis. Conversely, there is evidence that TLR3 has a protective role in EAE. Finally, there are reports of protective as well as pathogenic roles for TLR9 in EAE and for TLR2 in arthritis, and further study is required to define the potential of these TLRs as targets in multiple sclerosis and rheumatoid arthritis.
Indirect modulation of T cells by TLRs
There is growing evidence that the activation of PRRs on innate immune cells by pathogens or PAMPs can lead to a breakdown in self tolerance and bystander activation of autoreactive T H 1 or T H 17 cells. This supports the link between infection and autoimmunity.
Activation of pathogenic T cells.
There is evidence that PAMP-induced secretion of pro-inflammatory cytokines from monocytes and DCs promotes the induction and proliferation of T H 17 cells 7, 74, 75 (FIG. 3) .
For example, human monocytes stimulated with LPS, zymosan, flagellin or lipoteichoic acid promote IL-17 production by human CD4 + T cells that are activated using a CD3-specific antibody 74 . The TLR-induced signal was not identified, but addition of IL-6 or TGFβ inhibited IL-17 production in this setting. Furthermore, Candida albicans hyphae selectively promote T H 17 cell induction by inducing IL-23 but not IL-12 production from human monocytes and DCs 76 . TLR3, TLR4 or TLR9 ligands induce MYD88-dependent production of cytokines from DCs, and this promotes the differentiation of T H 17 cells 18 . Moreover, the TLR4 ligand LPS promotes IL-17 production by antigen-specific memory T cells in mice through the induction of IL-1 and IL-23 production by DCs 75 . Finally, TLR2 agonists have been shown to promote the differentiation of mouse T H 17 cells in vitro 62 . T H 17 cells can also be induced independently of TLR and NLR activation, through the activation of dectin 1 by the β-glucan curdlan, which promotes IL-6, TNF and IL-23 production by DCs 77 . Similarly, bacterial ligands of NOD2, such as muramyl dipeptide (MDP), have been shown to drive IL-17 production by human memory T cells by stimulating IL-1 and IL-23 production by DCs 7 . Finally, it has been reported that commensal microorganisms can promote the differentiation of T H 17 cells in the lamina propria of mice that are deficient in MYD88 and TLR3, suggesting that TLR and IL-1R signalling is not essential for the induction of T H 17 cells in the gut 78 .
Modulation of T cell-mediated autoimmunity.
The induction of experimental autoimmune diseases (such as EAE, EAU and CIA) in animals very often involves immunization with an autoantigen in the presence of CFA. The killed M. tuberculosis in CFA promotes the expression of innate pro-inflammatory cytokines that direct the induction of T H 1 and T H 17 cells. M. tuberculosis has been shown to activate the NLRP3 inflammasome, which promotes IL-1β and IL-18 production 8 , and to activate TLRs, leading to the production of IL-6 and IL-23; collectively, these cytokines drive the induction of T H 17 and T H 1 cells.
There have been several attempts to replace M. tuberculosis by purified PAMPs (TABLE 2) . Unlike PLP in CFA, which induces potent EAE, active immunization with PLP in IFA containing CpG-ODNs failed to induce EAE, although mild disease was induced in naive recipients following the transfer of T cells from mice immunized with PLP and CpG-ODNs in IFA 79 . This effect was attributed to the fact that M. tuberculosis is a more potent adjuvant than CpG-ODNs for the induction of T H 17 cell responses. By contrast, immunization of C57BL/10.S mice that express a transgenic TCR specific for a PLP peptide (PLP 139-151 ) with this peptide and CpG-ODNs in IFA induced EAE in 73% of mice, whereas only 33% developed spontaneous disease 80 . . As certain commercial preparations of LPS are allegedly contaminated with TLR2 agonists, it is possible that its pro-inflammatory effect was mediated by a combination of TLR2 and TLR4 activation. The adjuvant effects of LPS and zymosan were absent in mice deficient for IL-1R-associated kinase 1 (IRAK1), suggesting that IL-1 or TLR signalling through the MYD88-independent pathway was involved 82 . Although agonists for individual TLRs, especially TLR2 or TLR9, may initiate the innate immune responses that drive the activation of self-reactive effector T cells, it appears that these responses are optimally driven by signals from two TLRs or from a TLR and an NLR or CLR. This may reflect the need for both a priming stimulus and a boosting stimulus. For example, the production of mature active IL-1β requires priming with a TLR ligand to induce pro-IL-1β expression, as well as a second signal from a PAMP or DAMP to activate the NLR inflammasome complex and associated caspase 1, which cleaves the pro-IL-1β into its active form (FIG. 1) . M. tuberculosis can provide both stimuli 8 , and this may explain why it is more effective than individual TLR agonists in inducing experimental autoimmunity.
Modulation of T Reg cells in autoimmunity.
In addition to activating effector T cells, TLR agonists can indirectly or directly modulate the function of T Reg cells. There is evidence that TLR activation can block T Reg cell responses, thereby breaking tolerance to self antigens [83] [84] [85] . For example, IL-6 production by TLRactivated DCs can inhibit the suppressive function of T Reg cells 84 . Furthermore, IL-1 and IL-6 production by TLR-activated mature DCs is required to reverse the compromised T Reg cell proliferative capacity (anergy) that is induced by immature DCs 86 . However, it has also been reported that TLR4 or TLR9 agonists can promote the generation of IL-10-secreting T Reg cells that inhibit CD4
+ and CD8 + effector T cells 13, 87 . This may be a strategy to limit immunopathology during infection, but it may also control sterile inflammation and prevent the development of autoimmunity. The expansion of induced T Reg cell populations by TLR agonists appears to be mediated through TLR-induced production of IL-10, TGFβ and other immunosuppressive molecules by innate immune cells 13 . These regulatory mechanisms may prevent the induction of infection-driven autoimmunity in most individuals, but their failure or attenuation, perhaps by environmental factors, may increase the risks of developing autoimmune diseases.
Direct modulation of T cells via TLRs
It is well established that TLR signalling in innate immune cells can indirectly promote T cell differentiation and proliferation through DC maturation and regulatory cytokine production. However, T cells also express TLRs, and evidence is emerging that TLR signalling in CD4 + and γδ T cells can promote cytokine secretion or regulate their function (FIG. 3) .
Modulation of effector CD4
+ T cells. TLR2 signalling in T H 1 cells promotes the proliferation of these cells and their production of IFNγ 88 . Moreover, stimulation with CpG-ODNs restored the proliferation in response to a CD3-specific antibody of highly purified naive T cells from mice deficient in protein kinase Cθ (PKCθ) 89 . PKCθ is involved in T cell differentiation, and PKCθ-deficient mice are resistant to experimental autoimmune myocarditis (EAM). Susceptibility to EAM was restored by in vivo administration of CpG-ODNs 89 , suggesting that TLR ligands may act directly on T cells to induce autoimmunity in vivo. Finally, stimulation of CD4 + T cells with Pam 3 Cys induced their proliferation and IL-17 production, which was enhanced by IL-23. By contrast, Tlr2 -/-mice were less susceptible to EAE, and loss of TLR2 in T H 17 cells reduced their ability to transfer EAE 62 .
Modulation of CD8 + T cells. CD8 + T cells are found in the CNS lesions of patients with multiple sclerosis, where they appear to be involved in myelin degradation and neuronal damage 90 . Although it is unclear how selfreactive CD8 + T cells are activated in auto immune diseases, the mechanism may involve the cross-presentation of autoantigens and bystander stimulation by PAMPs. It has been demonstrated that CD8 + T cells express TLRs 91, 92 . Stimulation of mouse CD8 + T cells with TLR2 agonists enhanced the proliferation of these cells in response to a CD3-specific antibody by lowering the threshold for co-stimulatory signals 93 . In addition, a TLR9 agonist (CpG-ODNs) has been shown to promote the release of IL-8 (also known as CXCL8) by purified human CD8 + T cells 92 . Thus, TLR agonists may promote the activation of self-reactive CD8 + T cells in certain autoimmune diseases.
Modulation of γδ T cells.
It has been reported that γδ T cells express TLR1, TLR2 and the CLR dectin 1, and secrete IL-17 in vitro following stimulation with ligands for TLR1 and TLR2 or for TLR2 and dectin 1, particularly in the presence of exogenous IL-23 (REF. 23 ). More recently, it has been shown that IL-17-producing γδ T cells express higher levels of TLR1, TLR2, TLR4, TLR6 and TLR9 than IL-17-secreting CD4 + T cells 62 . We have found that highly purified naive γδ T cells produce IL-17 in response to IL-1β and IL-23, or in response to stimulation by PAMP-activated DCs, in the absence of stimulation by CD3-or CD28-specific antibodies 6 . However, highly purified γδ T cells failed to respond directly to TLR agonists alone 8 95 . In human T Reg cells, which express TLR5, stimulation with flagellin and a CD3-specific antibody enhances the expression of forkhead box P3 (FOXP3) and their suppressive function 96 . The TLR2 ligand Pam 3 Cys induces the proliferation of mouse T Reg cells and, although this was associated with a temporary loss of T Reg cell suppressive activity, T Reg cell function was restored following removal of the TLR agonist 97 . It has also been reported that a TLR2 agonist enhanced the proliferation of T Reg cells, but also transiently suppressed FOXP3 expression and rendered CD4 + CD25 -effector T cells resistant to suppression by T Reg cells 98 . Interestingly, it was recently reported that polysaccharide A from the gut commensal bacterium B. fragilis binds to TLR2 on CD4 + T cells to promote IL-10 production and the proliferation of T Reg cells, which, in turn, inhibit T H 17 cells. This suggests that TLR2-mediated activation of T cells may promote tolerance, at least in the mucosa 99 . Most of the evidence to date suggests that the activation of T cells in response to TLR ligands is primarily indirect and mediated through TLR-induced activation of APCs. However, T cells do express TLRs, and the binding of TLR agonists to T cells can contribute to their activation; this applies to both effector T cells and T Reg cells. Some of the strongest evidence in this area supports a role for TLR2 in the activation of T Reg cells so, from this perspective, blocking TLR2 may attenuate T Reg cell function and might therefore be more applicable to treating cancer than to treating autoimmunity. However, studies in knockout mice have suggested that TLR2 may be a good therapeutic target in certain autoimmune diseases. Therefore, further study is required to decipher the relative contributions of direct versus indirect activation of effector T cells and T Reg cells by TLRs in different autoimmune diseases.
TLRs as drug targets for autoimmunity
The increasing evidence that the innate and adaptive immune responses that mediate autoimmune diseases are driven by the binding of PAMPs and DAMPs to TLRs and other PRRs has motivated the assessment of TLR-specific blocking antibodies and inhibitors of TLR signalling in preclinical models of inflammatory and autoimmune disorders.
Proof-of-principle has been provided by studies using TLR-knockout mice. For example, experimental arthritis is attenuated in Tlr4 -/-mice, and this is associated with decreased T H 17 cell responses, suggesting that TLR4 may be a good upstream target for preventing IL-17 production in rheumatoid arthritis 11 . Indeed, it has already been shown that a TLR4 antagonist can treat arthritis in two mouse models 69 . Moreover, a synthetic TLR4 antagonist, the lipid A mimetic CRX-526, has been shown to inhibit the development of dextran-sulphate sodium (DSS)-induced colitis and of colitis in mice deficient for multidrug resistance gene 1A 100 . Similarly, a rat TLR4-specific monoclonal antibody (termed 1A6) reduced inflammation in DSSinduced colitis in mice 101 . A humanized TLR4-specific antibody has been developed by NovImmune and is currently undergoing preclinical evaluation as a potential therapy for inflammatory bowel disease. The lipid A mimetic eritoran (E5564; Eisai Co.), which interferes with the formation of the TLR4-MD2-LPS complex, is an effective inhibitor of LPS-induced shock in mice 102 , but did not meet its primary endpoint in patients with severe sepsis in a Phase III clinical trial 103 . TLR2 and nucleic acid-binding TLRs are also major targets for the treatment of various inflammatory and autoimmune diseases. EAE is attenuated in Tlr2 -/-mice, suggesting that the TLR2 signalling pathway may be a drug target for the treatment or prevention of multiple sclerosis 62 . A TLR2-specific antibody developed by Opsona Therapeutics has been shown to be effective in a mouse model of myocardial ischaemia-reperfusion injury 104 , and a humanized version of the antibody (OPN-305) has recently entered Phase I clinical trials.
Antagonists of TLR7, TLR8 or TLR9 -including CPG 52364 (Pfizer), IRS-954 (Dynavax) and IMO-3100 (Idera) -have also shown efficacy in mouse models of SLE and other autoimmune diseases, and these drugs have recently entered clinical trials 5 . These studies provide evidence that the inhibition of TLR signalling in response to exogenous PAMPs or endogenous DAMPs is a safe therapeutic approach in humans and has the potential to treat autoimmune diseases.
Conclusions and perspectives
Epidemiological studies have linked infection with the development or exacerbation of autoimmune diseases. Furthermore, enhanced expression of TLRs and their agonists in diseased tissues provides indirect evidence that innate immune responses mediated through TLRs and other PRRs contribute to autoimmune inflammation. More convincing evidence is provided by mouse models in which defects in expression or signalling via TLRs are associated with the attenuation of the innate and adaptive immune responses that mediate autoimmunity. Conversely, administration of exogenous TLR agonists to mice can promote or exacerbate autoimmunity.
In the absence of infection, sterile inflammation can be initiated by the release of DAMPs or alarmins from necrotic cells (FIG. 4) . It has recently been suggested that MAMPs derived from pathogens or commensal microorganisms bind to PRRs, but do not by themselves trigger host immune responses 105 . To overcome homeostatic immune regulation, innate immune cells require activation by MAMPs together with DAMPs, which are released from host cells following injury or pathogen-induced cell death 105 . This is consistent with the association between infections and autoimmunity, but it is not compatible with the view that commensal bacteria alone can precipitate autoimmune diseases, unless the second signal for innate activation is provided by injury-induced cell death.
Unless there is preferential expression of individual TLRs or their agonists in the affected tissues, there is likely to be redundancy between different TLRs, and between TLRs and other PRRs. Nevertheless, there is already evidence from mouse models that blocking a single TLR, especially TLR2, TLR4 or TLR9, may be sufficient for the inhibition of the innate responses that promote inflammation and autoimmunity. However, this effect may be disease dependent; for example, TLR4 inhibition ameliorates arthritis, and TLR2 inhibition dampens EAE.
Evidence from Phase III clinical trials indicates that drugs that broadly inhibit innate immune responses or completely block the induction or function of effector T cells are likely to significantly compromise host protective immunity. For example, a higher incidence of infections, including serious infections, was observed in patients with psoriasis who were treated with an IL-12p40-specific antibody, ustekinumab 106 (which blocks T H 1 and T H 17 cell responses), and in patients with gouty arthritis who were treated with an IL-1β-specific blocking antibody, canakinumab 107 , than in controls. Although these new drugs have significantly improved efficacies compared with existing therapies, more selective inhibition of specific pathways that are involved in inflammation in a particular tissue or that are relevant to a particular disease may not involve the same risks. If individual TLRs are proven to have dominant roles in particular autoimmune diseases, then it is possible that targeting TLRs (especially extracellular TLRs using inhibitory antibodies) may provide a safe and effective therapeutic approach for certain inflammatory and T cell-mediated autoimmune diseases. 
